Pfizer researching oral medication to prevent COVID-19.
On Monday, Pfizer Inc. (PFE.N) said that it is launching the mid-to-late stage of testing its oral antiviral drug investigational to prevent COVID-19 infections among people who have had contact with the virus.
The company, along with its competitors, including U.S.-based Merck & Co Inc (MRK.N) and Swiss pharmaceutical Roche Holding AG (ROG.S), have been striving to develop the first antiviral drug for COVID-19.
Pfizer has announced it will investigate the drug PF07321332 with as many as 2,660 adults aged 18 or older who reside in the same home as a person who has a confirmed symptomatic COVID-19 disease.
The trial will test the PF-07321332 medication with a lower dose of ritonavir. It is an older medication commonly used in combination treatment in the treatment of HIV infection.
Merck and its partner Ridgeback Biotherapeutics revealed that earlier in the month, they were able to enroll patients in a clinical trial in the final stages of their drug molnupiravir, an experimental drug to prevent COVID-19 infections.
Pfizer had previously announced this month that it was launching an intermediate-to-late-stage study of PF-07321332 to treat COVID-19 among non-hospitalized affected adult patients.
A Blogger, Author, and a speaker! Shamik Halder is recognized as a journalist in a newspaper and Admin of NewsGater.com. He loves to write about Today news, Breaking news, Entertainment, etc.
Email: [email protected]